株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

RACアルファセリン/トレオニンプロテインキナーゼ:パイプライン製品の分析

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 366670
出版日 ページ情報 英文 71 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
RACアルファセリン/トレオニンプロテインキナーゼ:パイプライン製品の分析 RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H2 2017
出版日: 2017年11月07日 ページ情報: 英文 71 Pages
概要

当レポートでは、RACアルファセリン/トレオニンプロテインキナーゼを標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

RACアルファセリン/トレオニンプロテインキナーゼ 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Almac Discovery Ltd
  • ArQule Inc
  • AstraZeneca Plc
  • Bayer AG
  • Merck & Co Inc
  • Novartis AG
  • Rexahn Pharmaceuticals Inc

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC1125TDB

Summary:

According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2017'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene. It regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine or threonine phosphorylation of a range of downstream substrates. It regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A and GSK3B resulting in inhibition of its kinase activity. It act as key modulator of the AKT-mTOR signaling pathway controlling the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I).

The report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2017' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 7, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Breast Cancer, Endometrial Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Cervical Cancer, Fallopian Tube Cancer, Melanoma, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Small-Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Anal Cancer, Colorectal Cancer, Congenital Vascular Malformation, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Lymphoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Renal Cell Carcinoma, Multiple Hamartoma Syndrome, Neuroendocrine Cancer, Orphan Diseases, Proteus Syndrome, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sickle Cell Disease and Solid Tumor.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)
  • The report reviews RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Overview
    • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • Almac Discovery Ltd
    • ArQule Inc
    • AstraZeneca Plc
    • Bayer AG
    • Merck & Co Inc
    • Novartis AG
    • Rexahn Pharmaceuticals Inc
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Drug Profiles
    • ALM-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARQ-092 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-5363 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BAY-1125976 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-2206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-2206 + selumetinib sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NISC-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RX-0201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RX-0201N - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit AKT1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Akt1/2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit FAK, PKC alpha and AKT-1 for Breast Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trametinib dimethyl sulfoxide + uprosertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • uprosertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Dormant Products
  • RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 07, 2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
      • May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting
      • Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
      • Jun 06, 2016: Rexahn Pharmaceuticals Presents Clinical Data on Archexin at the 2016 ASCO Annual Meeting
      • Apr 20, 2016: Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin at the 2016 American Association for Cancer Research Annual Meeting
      • Apr 20, 2016: Rexahn Pharmaceuticals Presents pre-Clinical Trial Data For Archexin-Nano At The 2016 American Association For Cancer Research Annual Meeting
      • Feb 08, 2016: Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma
      • Feb 02, 2016: Almac Discovery Secures Patent Protection for Novel allosteric Akt inhibitor (ALM301)
      • Jan 28, 2016: ArQule Provides Update on ARQ 092
      • Jan 11, 2016: Rexahn Pharmaceuticals Archexin Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study
      • Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092
      • Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
      • Nov 05, 2015: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin at the 14th International Kidney Cancer Symposium
      • Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics
      • Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Almac Discovery Ltd, H2 2017
  • Pipeline by ArQule Inc, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by Bayer AG, H2 2017
  • Pipeline by Merck & Co Inc, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Rexahn Pharmaceuticals Inc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top